Harbor BioSciences retains the rights to these products in US and rest of the world, and CIPI will provide the company all the pre-clinical and clinical data it generates.
The three license agreements include Harbor BioSciences compounds HE2000, HE3235 (Apoptone) and HE3286 (Triolex) for any clinical use in the People’s Republic of China and Hong Kong.
CIPI plans to develop the three compounds for major indications such as diabetes, cancer, inflammation and infectious diseases.
Under the agreement, Harbor BioSciences will receive milestone payments for Triolex, Apoptone and HE2000, excluding infectious diseases, following the completion of Phase II and III clinical studies and upon clearance by SFDA.
Harbor BioSciences will also receive royalties depending upon net profits for the life of each agreement.
CIPI senior vice president Yu Xiong said CIPI is very excited to be working with Harbor BioSciences.
"The compounds that we licensed from Harbor BioSciences, with their demonstrated safety profile and activity, are compatible with new health initiatives of our government," Xiong said.